Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
3.070
-0.080 (-2.54%)
At close: Sep 15, 2025, 4:00 PM EDT
3.139
+0.069 (2.25%)
After-hours: Sep 15, 2025, 7:46 PM EDT
Grace Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
42.45M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | - | - | - |
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | - | - | - |
| Mar 31, 2021 | 196.00K | - | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Feb 29, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
GRCE News
- 11 days ago - Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 19 days ago - Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104 - GlobeNewsWire
- 4 weeks ago - Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update - GlobeNewsWire
- 2 months ago - Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104 - GlobeNewsWire
- 3 months ago - Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update - GlobeNewsWire
- 3 months ago - Grace Therapeutics to Participate in the 2025 BIO International Conference - GlobeNewsWire
- 5 months ago - Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104 - GlobeNewsWire
- 6 months ago - Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors - GlobeNewsWire